Market Place
Sourcing Support
Innovent`s Mazdutide Shows Superiority Over Dulaglutide In Diabetes Trial
11 Sep 2024 //
PR NEWSWIRE
Innovent Annouces Multiple Clinical Study Results of Mazdutide
01 Sep 2024 //
PR NEWSWIRE
Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug
23 Jul 2024 //
BIOSPACE
Innovent Updates Data From Mazdutide GLORY-1 Study And Biomedicine Pipeline
27 Jun 2024 //
PR NEWSWIRE
Innovent To Present Mazdutide Results At ADA Scientific Sessions
12 Jun 2024 //
PR NEWSWIRE
Lilly`s next-gen obesity drug brings Innovent ph. 3 diabetes win
09 May 2024 //
FIERCE BIOTECH
Innovent`s First NDA of Mazdutide has been Accepted by the NMPA of China
07 Feb 2024 //
PR NEWSWIRE
Innovent`s Phase III obesity treatment trial meets all endpoints
10 Jan 2024 //
CLINICAL TRIALS ARENA
Innovent Announces the First Phase 3 Trial of Mazdutide in Chinese Adults
08 Jan 2024 //
PR NEWSWIRE
Innovent Dosed First Participant in Phase 3 Clinical Study of Mazdutide
01 Jan 2024 //
PR NEWSWIRE
Innovent Announces Publication of Mazdutide Phase 2 Full Results
17 Dec 2023 //
PR NEWSWIRE
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results
21 Nov 2023 //
PR NEWSWIRE
Innovent Announces Robust Weight Loss Efficacy of Higher Dose 9 mg Mazdutide
29 Oct 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.